Ind-Swift Labs.

{
  "main_header": {
    "sid": 393806,
    "name": "Ind-Swift Labs.",
    "stock_name": "Ind-Swift Labs.",
    "full_name": "Ind-Swift Laboratories Ltd",
    "name_url": "stocks-analysis/ind-swift-labs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "113.34",
    "chg": 5.93,
    "chgp": "5.52%",
    "dir": 1,
    "prev_price": "107.41",
    "mcapval": "917.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 532305,
    "symbol": "INDSWFTLAB",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE915B01019",
    "curr_date": "Jan 30",
    "curr_time": "",
    "bse_nse_vol": "7.86 lacs",
    "exc_status": "Active",
    "traded_date": "Jan 30, 2026",
    "traded_date_str": "2026 01 30",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/ind-swift-labs-393806-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "text": "Part of MojoOne Strategy",
      "type": "HT",
      "url": "https://www.marketsmojo.com/mojopro/strategy/1",
      "ismore": 0,
      "all_data": [],
      "is_blur": 1,
      "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/ind-swift-labs-393806-0&utm_source=Spage_Score_PartofStrategies"
    }
  },
  "news": {
    "results": [
      {
        "title": "Ind-Swift Laboratories Q2 FY26: Recovery Gains Momentum Amid Operational Challenges",
        "link": "https://www.marketsmojo.com/news/result-analysis/ind-swift-laboratories-q2-fy26-recovery-gains-momentum-amid-operational-challenges-3813424",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/IndSwiftLaborat_quaterlyResult_3813424.png",
        "date": "2026-01-31 21:45:55",
        "description": "Ind-Swift Laboratories Limited, the Chandigarh-based active pharmaceutical ingredient (API) manufacturer, reported a consolidated net profit of ₹7.99 crores for Q2 FY26 (July-September 2025), marking a dramatic turnaround from the ₹0.41 crores reported in the corresponding quarter last year. This represents an extraordinary year-on-year growth of 1,848.78%, though the quarter-on-quarter performance showed a marginal decline of 8.89% from Q1 FY26's ₹8.77 crores. The stock surged 5.52% following the results announcement, closing at ₹113.34 on January 30, 2026, reflecting renewed investor confidence in the company's recovery trajectory."
      },
      {
        "title": "Are Ind-Swift Laboratories Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-ind-swift-laboratories-ltd-latest-results-good-or-bad-3813305",
        "imagepath": "",
        "date": "2026-01-31 19:19:29",
        "description": "Ind-Swift Laboratories Ltd's latest financial results for Q2 FY26 present a complex picture. The company reported a net profit of ₹7.99 crores, reflecting a significant year-on-year growth of 1,848.78% compared to the same quarter last year, which had a notably weak base. However, this figure represents an 8.89% decline on a quarter-on-quarter basis. \n\nNet sales for the same period reached ₹152.64 crores, marking a year-on-year increase of 1,176.25%. Yet, the sequential performance shows a slight contraction of 0.06% from the previous quarter. This stagnation in revenue raises concerns about the sustainability of the recovery observed in prior quarters.\n\nOperating margins have notably compressed, falling to 0.96% from 2.36% in the previous quarter. This decline indicates increasing cost pressures, despite stable revenue levels. The operating profit before depreciation, interest, tax, and other income (PBDIT..."
      },
      {
        "title": "When is the next results date for Ind-Swift Laboratories Ltd?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-ind-swift-laboratories-ltd-3810242",
        "imagepath": "",
        "date": "2026-01-29 23:16:11",
        "description": "The next results date for Ind-Swift Laboratories Ltd is scheduled for January 31, 2026...."
      },
      {
        "title": "Ind-Swift Laboratories Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/ind-swift-laboratories-ltd-is-rated-strong-sell-3802993",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/IndSwiftLaborat_mojoScore_3802993.png",
        "date": "2026-01-24 10:10:27",
        "description": "Ind-Swift Laboratories Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 12 August 2025. However, the analysis and financial metrics presented here reflect the stock’s current position as of 24 January 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Why is Ind-Swift Laboratories Ltd falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-ind-swift-laboratories-ltd-fallingrising-3793140",
        "imagepath": "",
        "date": "2026-01-17 00:48:54",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Strong Quarterly Performance Spurs Investor Optimism</strong></p>\n<p>Ind-Swift Laboratories Ltd’s recent surge can be primarily attributed to its impressive quarterly results declared in September 2025, which marked a turnaround after four consecutive quarters of negative performance. The company reported net sales of ₹152.64 crores, reflecting an extraordinary growth of 1176.25% compared to previous quarters. This remarkable increase in sales was accompanied by a substantial rise in profit after tax (PAT), which soared by 1848.8% to ₹7.99 crores. Such a dramatic improvement in financial metrics has evidently rekindled investor confidence, as reflected in the stock’s strong upward momentum.</p>\n<p><strong>Outperformance Against Benchmarks and Sector</strong></p>\n<p>Ind-Swift Laboratories has..."
      },
      {
        "title": "Ind-Swift Laboratories Ltd Sees Mixed Technical Signals Amid Price Momentum Shift",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ind-swift-laboratories-ltd-sees-mixed-technical-signals-amid-price-momentum-shift-3791270",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/IndSwiftLaborat_technicaldot_3791270.png",
        "date": "2026-01-14 08:01:04",
        "description": "Ind-Swift Laboratories Ltd has experienced a notable shift in price momentum, reflected in a complex interplay of technical indicators that suggest a cautious outlook for investors. Despite a strong intraday rally pushing the stock price to ₹104.13, technical signals remain mixed, with some indicators pointing to mild bearishness while others hint at potential bullish momentum."
      },
      {
        "title": "Ind-Swift Laboratories Ltd Forms Death Cross, Signalling Bearish Trend Ahead",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ind-swift-laboratories-ltd-forms-death-cross-signalling-bearish-trend-ahead-3784845",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/IndSwiftLaborat_dealthcross_3784845.png",
        "date": "2026-01-07 18:01:35",
        "description": "Ind-Swift Laboratories Ltd has recently formed a Death Cross, a significant technical indicator where the 50-day moving average (DMA) crosses below the 200-DMA. This development signals a potential shift towards a bearish trend, reflecting deteriorating momentum and long-term weakness in the stock’s price action."
      },
      {
        "title": "Ind-Swift Laboratories Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/ind-swift-laboratories-ltd-is-rated-strong-sell-3778769",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/IndSwiftLaborat_mojoScore_3778769.png",
        "date": "2026-01-02 10:10:03",
        "description": "Ind-Swift Laboratories Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 12 Aug 2025, reflecting a reassessment of the company’s outlook. However, all fundamentals, returns, and financial metrics discussed here are based on the stock’s current position as of 02 January 2026, providing investors with the latest comprehensive view of the company’s performance and prospects."
      },
      {
        "title": "Ind-Swift Labs. Sees Revision in Market Assessment Amid Challenging Fundamentals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/ind-swift-labs-downgraded-to-strong-sell-amid-deteriorating-fundamentals-3765550",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/IndSwiftLabs_mojoScore_3765550.png",
        "date": "2025-12-22 10:10:35",
        "description": "Ind-Swift Labs., a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market assessment reflecting shifts in its fundamental and technical outlook. This adjustment highlights evolving perspectives on the company’s financial health, valuation risks, and market positioning amid a backdrop of subdued returns and operational challenges."
      }
    ],
    "total": 153,
    "sid": "393806",
    "stock_news_url": "https://www.marketsmojo.com/news/ind-swift-laboratories-393806"
  },
  "announcements": [
    {
      "caption": "Board Meeting Intimation for Meeting Of The Board Of Directors Scheduled To Be Held On January 31 2026.",
      "datetime": "28-Jan-2026",
      "details": "Ind-Swift Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/01/2026 inter alia to consider and approve unaudited financial results for the quarter and nine months ended December 31 2025 on standalone and consolidated basis.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
      "datetime": "20-Jan-2026",
      "details": "Please refer attached pdf.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
      "datetime": "14-Jan-2026",
      "details": "Investor Presentation",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Ind-Swift Laboratories Ltd has declared <strong>10%</strong> dividend, ex-date: 20 Sep 11",
          "dt": "2011-09-20",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Ind-Swift Laboratories Q2 FY26: Recovery Gains Momentum Amid Operational Challenges

2026-01-31 21:45:55

Ind-Swift Laboratories Limited, the Chandigarh-based active pharmaceutical ingredient (API) manufacturer, reported a consolidated net profit of ₹7.99 crores for Q2 FY26 (July-September 2025), marking a dramatic turnaround from the ₹0.41 crores reported in the corresponding quarter last year. This represents an extraordinary year-on-year growth of 1,848.78%, though the quarter-on-quarter performance showed a marginal decline of 8.89% from Q1 FY26's ₹8.77 crores. The stock surged 5.52% following the results announcement, closing at ₹113.34 on January 30, 2026, reflecting renewed investor confidence in the company's recovery trajectory.

Read full news article

Are Ind-Swift Laboratories Ltd latest results good or bad?

2026-01-31 19:19:29

Ind-Swift Laboratories Ltd's latest financial results for Q2 FY26 present a complex picture. The company reported a net profit of ₹7.99 crores, reflecting a significant year-on-year growth of 1,848.78% compared to the same quarter last year, which had a notably weak base. However, this figure represents an 8.89% decline on a quarter-on-quarter basis. Net sales for the same period reached ₹152.64 crores, marking a year-on-year increase of 1,176.25%. Yet, the sequential performance shows a slight contraction of 0.06% from the previous quarter. This stagnation in revenue raises concerns about the sustainability of the recovery observed in prior quarters. Operating margins have notably compressed, falling to 0.96% from 2.36% in the previous quarter. This decline indicates increasing cost pressures, despite stable revenue levels. The operating profit before depreciation, interest, tax, and other income (PBDIT...

Read full news article

When is the next results date for Ind-Swift Laboratories Ltd?

2026-01-29 23:16:11

The next results date for Ind-Swift Laboratories Ltd is scheduled for January 31, 2026....

Read full news article

Ind-Swift Laboratories Ltd is Rated Strong Sell

2026-01-24 10:10:27

Ind-Swift Laboratories Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 12 August 2025. However, the analysis and financial metrics presented here reflect the stock’s current position as of 24 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Why is Ind-Swift Laboratories Ltd falling/rising?

2026-01-17 00:48:54

Strong Quarterly Performance Spurs Investor Optimism

Ind-Swift Laboratories Ltd’s recent surge can be primarily attributed to its impressive quarterly results declared in September 2025, which marked a turnaround after four consecutive quarters of negative performance. The company reported net sales of ₹152.64 crores, reflecting an extraordinary growth of 1176.25% compared to previous quarters. This remarkable increase in sales was accompanied by a substantial rise in profit after tax (PAT), which soared by 1848.8% to ₹7.99 crores. Such a dramatic improvement in financial metrics has evidently rekindled investor confidence, as reflected in the stock’s strong upward momentum.

Outperformance Against Benchmarks and Sector

Ind-Swift Laboratories has...

Read full news article

Ind-Swift Laboratories Ltd Sees Mixed Technical Signals Amid Price Momentum Shift

2026-01-14 08:01:04

Ind-Swift Laboratories Ltd has experienced a notable shift in price momentum, reflected in a complex interplay of technical indicators that suggest a cautious outlook for investors. Despite a strong intraday rally pushing the stock price to ₹104.13, technical signals remain mixed, with some indicators pointing to mild bearishness while others hint at potential bullish momentum.

Read full news article

Ind-Swift Laboratories Ltd Forms Death Cross, Signalling Bearish Trend Ahead

2026-01-07 18:01:35

Ind-Swift Laboratories Ltd has recently formed a Death Cross, a significant technical indicator where the 50-day moving average (DMA) crosses below the 200-DMA. This development signals a potential shift towards a bearish trend, reflecting deteriorating momentum and long-term weakness in the stock’s price action.

Read full news article

Ind-Swift Laboratories Ltd is Rated Strong Sell

2026-01-02 10:10:03

Ind-Swift Laboratories Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 12 Aug 2025, reflecting a reassessment of the company’s outlook. However, all fundamentals, returns, and financial metrics discussed here are based on the stock’s current position as of 02 January 2026, providing investors with the latest comprehensive view of the company’s performance and prospects.

Read full news article

Ind-Swift Labs. Sees Revision in Market Assessment Amid Challenging Fundamentals

2025-12-22 10:10:35

Ind-Swift Labs., a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market assessment reflecting shifts in its fundamental and technical outlook. This adjustment highlights evolving perspectives on the company’s financial health, valuation risks, and market positioning amid a backdrop of subdued returns and operational challenges.

Read full news article

View All News